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vention. The main intervention areas were: adverse drug
effects; incorrect dosage; polypharmacy, and drug-drug,
drug-disease and drug-food interactions. Based on this
data, the pharmacist suggested specific changes in drug
treatment including route of administration, changing
dosing, eliminating drug interactions and preventing life-
threatening drug combinations. In addition the clinical
pharmacist provides pharmaceutical information to phy-
sicians and nursing staff.
RESULTS: We reviewed approximately 2300 medical
records and found one or more interventions in 11% of
the cases. The main type of interventions were: 99
(38.9%) unnecessary drugs; 51 (20%) incorrect dose; 47
(18.5%) drug information; 26 (10.2%) adverse drug re-
action; 17 (6.6%) drug-drug interactions, and 14 (5.5%)
therapeutic drug monitoring. It should be emphasized
that 112 drug interactions with varying degrees of sever-
ity were prevented. The physicians, in 96% of all inter-
ventions, accepted the clinical pharmacist’s recommenda-
tions.
CONCLUSION: The results demonstrate that the clinical
pharmacist contributes substantially to the quality of pa-
tient care involving drug-related problems. In addition,
this intervention may reduce length of hospital stay and
lower drug costs.
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OBJECTIVE: To estimate the in-hospital costs of blood
products in German hospitals.
METHODS: Data on personnel-time and material-resource
utilisation associated with blood products were collected
as part of a health-economic study on hospital costs for
Coronary Artery Bypass Graft patients with and without
rethoracotomy in Germany. The real cost to hospitals for
blood products was then calculated based on these data.
The transfusion departments in four hospitals each com-
pleted a questionnaire, giving details of materials and time
required to obtain or to prepare erythrocytes (autologous
and homologous blood) and autologous fresh frozen
plasma. Hospital administration departments provided in-
formation from which personnel costs were calculated.
RESULTS: For homologous erythrocytes, total costs
were 194 DM (99 Euro) per unit of donor red blood
cells. Logistics, testing and materials (e.g. use of transfu-
sion instruments) amounted to a total of 77 DM (39
Euro) in addition to the acquisition costs. On average,
about 50 minutes were spent on ordering, buying, stor-
age, administration, disposal and testing of the banked
blood. The production of one unit from autologous
blood cost 223 DM (114 Euro). Time taken by staff
made up a significant portion of these costs. On average,
130 minutes were necessary for collection of blood, prep-
aration, testing, storage, administration, disposal and re-
testing before the operation. Fresh frozen plasma was ob-
tained during preparation of autologous blood and cost
an extra 31 DM (16 Euro) per unit.
CONCLUSION: This economic analysis of blood prod-
ucts shows that both personnel and material costs for ad-
ditional processing of blood products amount to a signif-
icant part of the total hospital costs. Blood-product
acquisition costs alone may lead to an underestimation of
the economic benefit associated with treatments that po-
tentially reduce the need for blood products.
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OBJECTIVES: To estimate the number of patients and
costs for the treatment of selected diseases in Switzerland,
depending on physical activity level. Calculation of acci-
dents due to sport or other causes.
METHODS: Top-down approach, modeling the number
of cases and deaths due to coronary heart disease (CHD),
hypertension, non-insulin-dependent diabetes (NIDD),
mammary cancer, colon cancer, lower back pain (LBP),
brief recurrent depression, osteoporosis. Distinction by
activity level (active or not). Decision tree model for cal-
culating the number of accidents, disability, and deaths
due to sports and general accidents. Inclusion of direct
costs, indirect costs, and transfer payments. A compari-
son of disease and accident costs was not possible, be-
cause accidents could not be separated by activity level.
RESULTS: The burden of disease is 8.5 billion SFr in di-
rect and 6 billion SFr in indirect costs. The inactive popu-
lation (37%) incurs most of the direct costs (49%, 4.14
billion SFr). Diseases occurring in the active population
(61%) require 2.7 billion SFr a year. Each physically in-
active person costs 2595 SFr per year; active people,
1700 SFr per year. The risks attributable to physical inac-
tivity are: CHD, 24%; hypertension, 15%; NIDD, 24%;
mammary cancer, 12%; colon cancer, 25%; LBP, 12%;
depression, 44%; osteoporosis, 27%. The proportion of
costs for diseases caused by physical inactivity is 16%.
Total number of general accidents is 670,000, plus
299,000 sports-related accidents. 1875 accident-related
deaths occur, with only 161 (9%) of them caused by
sport. The ratio of the yearly direct costs of non-sport/
sport-related accidents is 3.4 / 1.1 billion SFr, and the ra-
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tio of indirect costs is 6.3 / 2.3 billion SFr. Transfer costs
for disability payments are 37 million SFr per year (86%
for non-sport accidents).
CONCLUSIONS: Promotion of physical activity is cost
saving in terms of disease costs. Our findings regarding
the disease costs per patient are consistent with recently
published results for the US.
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OBJECTIVES: Prescribing errors are a major cause of ia-
trogenic morbidity in hospitalised patients and interven-
tions aimed at preventing these errors may result in mon-
etary benefits and health gains. We performed a study to
estimate whether costs of prevention are outweighed by
these benefits.
METHODS: During a one-week period in 2000, all med-
ication orders were analysed in two Dutch hospitals
(1100 beds in total) and prescribing errors were identi-
fied and classified. Medical and nursing staff were not
aware of the procedure. A cost-benefit analysis was per-
formed from the health-care perspective. Net cost esti-
mates were based on the time invested by the hospital
staff to correct the error and included potential time sav-
ings for the nursing staff. Estimates of net benefits were
based on the possible consequences of the prescribing er-
ror for nursing care, drug use, laboratory tests, length of
stay and potential interventions.
RESULTS: In total, 3540 medication orders were analy-
sed, of which 351 ( 10%) contained prescribing errors.
Classification of prescribing errors revealed that  60%
of errors would be without clinical consequences, whereas
 40% of errors would at least require extra monitoring
from the nursing staff. Net costs related to time invest-
ment of the pharmacy staff were  €300. Estimated net
benefits of this time investment were  €9900. These net
benefits were broken down as follows: extra care from
nursing staff of €300; extra drug use and laboratory tests
of €1900; extra length of hospital stay of €6000; acute
coronary intervention of €1700.
CONCLUSIONS: It can be concluded that net costs of
time investment by the pharmacy staff to prevent pre-
scribing errors were more than offset by related net bene-
fits.
PHP22
PERCEIVED QUALITY OF LIFE AND MEDICINE 
CONSUMPTION IN ELDERLY OUTPATIENTS
Goicoechea A1, Muñoz M1, Mauleón J2
1The Basque Country University, Vitoria-Gasteiz, Spain; 2Araba 
Country Council, Vitoria-Gasteiz, Spain
OBJECTIVE: To investigate the incidence of several
common chronic pathologies on the perceived quality of
life (PQL) in elderly outpatients ( 65 years), in Spain,
and its possible relation with the consumption of medi-
cines.
METHODS: A prospective analysis was carried out using
1500 questionnaires (Confidence limit 95%; Relative
error (/) 8%), following a protocol inspired in the
OARS design (Duke University). Subjects were chosen
following a stratified random design according to the
method of proportional fixation (geographical location,
age and sex). The survey was carried out by 17 social
workers, who received specific training.
RESULTS: 21 illnesses were determined, with varying de-
grees of prevalence in the population studied: arthritis
(57.4%); high blood pressure (30%); varicose veins
(23.3%); insomnia (21%); heart troubles (17%); bron-
chitis (14%), and diabetes (12%). Of the more prevalent
illnesses according to the subjects, those that most af-
fected PQL were heart troubles (70%), bronchitis (68%),
arthritis (65%), asthma (60%), diabetes (60%) and in-
somnia (45%). Of all the pathologies, a significant in-
crease in medicine consumption was found among pa-
tients in whom the illness was detrimental to their PQL,
as opposed to those who stated that they did not perceive
changes in their quality of life owing to the illness. Medi-
cine consumption was reported as follows: high blood
pressure (85% vs 22%); diabetes (78% vs 25%) and
asthma (72% vs 19%). Neither sex, age nor geographic
location affected these results significantly.
CONCLUSION: The results obtained show a remarkable
increase in the consumption of medicines in cases in
which the pathology and the subjective perception of the
illness affected their PQL. The increase was most notable
among patients in whom the illness affected their per-
ceived quality of life.
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OBJECTIVES: Older people are the largest consumers of
hospital care. They have longer hospital stays compared
to younger people. Reducing length of stay has become
an important feature of hospital treatment, but readmis-
sion is a common problem. We tried to identify medical,
social and demographic factors associated with readmis-
sion and suggest preventive measures to improve quality
of care of older people.
METHODS: A retrospective medical record review of a
random sample of 50 patients (aged  75 years) who had
unplanned readmission within 28 days of discharge
formed the study group. Another 50 patients who were
